Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D | P25100 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 3/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15816469 | 0.85 | ADRA1D (0.51) | ADRA1DALDH1A1MAPK10KDM4EUSP2 | |
| SCHEMBL29001267 | 0.82 | MAPK10 (0.51) | ALDH1A1MAPK10KDM4EUSP2BRD4 | |
| SCHEMBL1191685 | 0.82 | MAPK10 (0.45) | ADRA1DALDH1A1MAPK10KDM4EUSP2 | |
| SCHEMBL15815917 | 0.78 | ALDH1A1 (0.55) | ALDH1A1KDM4EMAPK14MAPTMEN1 | |
| SCHEMBL2285071 | 0.78 | ADRA1D (0.59) | ADRA1DALDH1A1BRD4MAPTLMNA | |
| SCHEMBL15836993 | 0.77 | ALDH1A1 (0.50) | ADRA1DALDH1A1MAPK10KDM4EBRD4 | |
| SCHEMBL20709920 | 0.75 | BRD4 (0.53) | ADRA1DBRD4 | |
| Ethane SCHEMBL13370815 | 0.75 | ALDH1A1 (0.51) | ALDH1A1MAPK10KDM4EBRD4MAPT | |
| SCHEMBL16899407 | 0.74 | MAPK14 (0.53) | ALDH1A1KDM4EBRD4MAPK14MAPT | |
| SCHEMBL5812520 | 0.73 | L3MBTL1 (0.52) | MAPK14MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6916933-B2 | 4-pyridinyl-n-acyl-l-phenylalanines | HOFFMAN-LA ROCHE INC. (US) | 2005-07-12 | — | — | US | disclosed |
| EP-1244625-B1 | 4-PYRIDINYL-N-ACYL-L-PHENYLALANINES | HOFFMANN LA ROCHE (CH) | 2005-06-15 | — | — | EP | disclosed |
| CN-1196682-C | 4-pyridyl-N-acyl-L-phenylalanine | HOFFMANN LA ROCHE (CH) | 2005-04-13 | — | — | CN | disclosed |
| US-20040127706-A1 | 4-Pyridinyl-n-acyl-l-phenylalanines | KAPLAN GERALD LEWIS (US) | 2004-07-01 | — | — | US | disclosed |
| CN-1402709-A | 4-pyridinyl-N-acyl-L-phenylalanines | HOFFMANN LA ROCHE (CH) | 2003-03-12 | — | — | CN | disclosed |
| EP-1244625-A1 | 4-PYRIDINYL-N-ACYL-L-PHENYLALANINES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-10-02 | — | — | EP | disclosed |
| US-20020133015-A1 | 4-pyridinyl-N-acyl-L-phenylalanines | KAPLAN GERALD LEWIS (US) | 2002-09-19 | — | — | US | disclosed |
| US-6388084-B1 | 4-pyridinyl-n-acyl-l-phenylalanines | HOFFMANN-LA ROCHE INC. | 2002-05-14 | — | — | US | disclosed |
| WO-2001042215-A1 | 4-PYRIDINYL-N-ACYL-L-PHENYLALANINES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127706-A1 | 4-Pyridinyl-n-acyl-l-phenylalanines | VCAM1, ICAM1, SELPLG | ADRA1D 327/4885ALDH1A1 81/4885MAPK10 2208/4885 |
| US-20020133015-A1 | 4-pyridinyl-N-acyl-L-phenylalanines | VCAM1, ICAM1, SELPLG | ADRA1D 327/4885ALDH1A1 81/4885MAPK10 2208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.